Racura Oncology Limited (ASX:RAC): What the HARNESS-1 Dose Escalation Means for RC220

Aditi Sarkar

11 November 2026 04:49 PM AEDT

Racura Oncology Limited (ASX:RAC): What the HARNESS-1 Dose Escalation Means for RC220

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

The HARNESS-1 safety committee cleared progression to the next planned RC220 dose.
The next planned dose is 100 mg/m² in combination with osimertinib.
The September 2026 Quarterly Report disclosed AUD 30.7 million in cash and equivalents.
Safety clearance at this stage does not demonstrate clinical efficacy.

Racura Oncology Limited (ASX:RAC) is a clinical-stage oncology company developing drug programmes centred on RC220, a formulation of bisantrene. Its 2026 activity includes clinical studies assessing the candidate in different treatment settings. In October, the company reported a safety-based dose-escalation decision in the HARNESS-1 trial for patients with EGFR-mutant non-small cell lung cancer, while its September-quarter report set out the resources available for continued research.

HARNESS-1 Progresses to the Next Dose

On 12 October 2026, Racura Oncology Limited (ASX:RAC) announced that the HARNESS-1 Safety Review Committee had cleared the trial to progress from the initial 50 mg/m² RC220 dose to the next planned 100 mg/m² dose, administered in combination with osimertinib. The company said the committee identified no dose-limiting toxicities or treatment-related safety concerns in the two patients evaluated during the relevant observation period.

HARNESS-1 is a Phase 1a/b study in patients with EGFR-mutant non-small cell lung cancer. Its early stages are primarily designed to evaluate dosing and tolerability. Permission to escalate therefore represents a defined procedural step in the trial, not proof that the combination improves cancer outcomes.

Safety Findings Require Careful Interpretation

Racura Oncology Limited (ASX:RAC) must continue to review safety as enrolment and treatment proceed. A cohort involving only two patients provides limited information about uncommon adverse events, longer-term tolerability or treatment effectiveness. Safety decisions made within a protocol can change when additional patients are treated or new information becomes available.

The distinction between safety and efficacy is important for an early-stage cancer study. Later assessments may examine tumour response and other endpoints, but any clinical conclusions must be based on reported data rather than inferred from a dose-escalation decision. Recruitment pace, eligibility criteria and the availability of trial sites can also influence when subsequent updates become available.

September Quarter Research and Liquidity

The company’s September 2026 quarterly activities report, released on 22 October, recorded cash and cash equivalents of AUD 30.7 million at 30 September 2026. It also stated that AUD 2.46 million, representing 80% of spending in the period, was directed towards Research and Development and drug Manufacturing activities. Those figures indicate the financial emphasis on clinical advancement and supporting drug supply.

For Racura Oncology Limited (ASX:RAC), the reported cash position is relevant because clinical programmes can extend across multiple phases, with expenditure dependent on study design, recruitment and manufacturing. Cash held at a quarter-end is not equivalent to revenue, and it does not establish whether future trials will succeed.

Other Trial Activity and Near-Term Priorities

The September-quarter report also noted expansion of the CPACS Phase 1 trial into South Korea and ethics approval for additional HARNESS-1 sites in New South Wales and Victoria. The company separately reported clinical progress at a cardio-oncology conference in October. These activities demonstrate that Racura has more than one active research workstream, although the endpoints and timelines are specific to each study.

Racura Oncology Limited (ASX:RAC) will need to report subsequent patient dosing, safety assessments and any protocol-defined clinical findings. Trial activity can be delayed or revised, and regulatory approval of a medicine is a separate process from permission to continue early-stage research.

Key Insights

Racura Oncology Limited (ASX:RAC) reported an October 2026 safety decision permitting a higher planned RC220 dose in HARNESS-1, supported by continuing Investment in research and a September-quarter cash balance of AUD 30.7 million. The principal uncertainties are clinical safety with further exposure, evidence of effectiveness and the resources needed for later development.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.